RESUMEN
The immunological response in the brain is crucial to overcome neuropathological events. Some inflammatory mediators, such as the immunoregulatory cytokine interleukin-6 (IL-6) affect neuromodulation and may also play protective roles against various noxious conditions. However, the fundamental mechanisms underlying the long-term effects of IL-6 in the brain remain unclear. We now report that IL-6 increases the expression and function of the neuronal adenosine A1 receptor, with relevant consequences to synaptic transmission and neuroprotection. IL-6-induced amplification of A1 receptor function enhances the responses to readily released adenosine during hypoxia, enables neuronal rescue from glutamate-induced death, and protects animals from chemically induced convulsing seizures. Taken together, these results suggest that IL-6 minimizes the consequences of excitotoxic episodes on brain function through the enhancement of endogenous adenosinergic signaling.
Asunto(s)
Interleucina-6/farmacología , Neuronas/efectos de los fármacos , Receptor de Adenosina A1/metabolismo , Transmisión Sináptica/efectos de los fármacos , Regulación hacia Arriba/efectos de los fármacos , Análisis de Varianza , Animales , Autorradiografía/métodos , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Corteza Cerebral/citología , Embrión de Mamíferos , Inhibidores Enzimáticos/farmacología , Fármacos actuantes sobre Aminoácidos Excitadores/farmacología , Potenciales Postsinápticos Excitadores/efectos de los fármacos , Potenciales Postsinápticos Excitadores/efectos de la radiación , Hipocampo/efectos de los fármacos , Hipocampo/fisiología , Interleucina-6/deficiencia , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Pentilenotetrazol/farmacología , Ensayo de Unión Radioligante/métodos , Receptor de Adenosina A1/genética , Convulsiones/inducido químicamente , Convulsiones/tratamiento farmacológico , Convulsiones/genética , Factores de TiempoRESUMEN
New N,5'-di- and N,2,5'-trisubstituted adenosine derivatives were synthesized in good overall yields. Appropriate 5-O-alkyl-substituted ribose moieties were coupled to 6-chloropurine or 2,6-dichloropurine via Vorbrüggen's glycosylation method. Subsequent amination and deprotection of the intermediates yielded compounds 18-35. Binding affinities were determined for rat adenosine A1 and A2A receptors and the human A3 receptor. The ability of compounds 18-35 to inhibit forskolin-induced (10 microM) cyclic AMP (cAMP) production and their ability to stimulate guanosine 5'-O-(3-[35S]thio)triphosphate ([35S]GTPgammaS) binding, via either the adenosine A1 receptor or the adenosine A3 receptor, were assessed. N-Cyclopentyl-substituted adenosine derivatives displayed affinities in the low nanomolar range for the adenosine A1 receptor, whereas N-(3-iodobenzyl)-substituted derivatives had high affinity for the adenosine A3 receptor. Compound 22 had the highest affinity for the adenosine A1 receptor (K(i) value of 16 nM), and compounds 20 and 26 had the highest affinities for the adenosine A3 receptor (K(i) values of 4 and 3 nM, respectively). A chlorine substituent at the 2-position either did not affect or slightly increased the adenosine A1 receptor affinity, whereas the A3 receptor affinity was affected differently, depending on the N-substituent. Furthermore, the introduction of chlorine slightly increased the A3/A1 selectivity ratio. At the 5'-position, an O-methyl substituent induced the highest adenosine A1 receptor affinity, whereas an O-ethyl substituent did so for the A3 receptor. All compounds showed partial agonistic effects in both the cAMP and [35S]GTPgammaS assays, although more marked in the latter assay. In general, the 2-chloro derivatives seemed to have lower intrinsic activities compared to the 2-H-substituted compounds on both the adenosine A1 and the adenosine A3 receptors. The compounds with an N-(3-iodobenzyl) substituent displayed the lowest intrinsic activities. Finally, all compounds also showed partially antagonistic behavior in the [35S]GTPgammaS assay.
Asunto(s)
Adenosina/síntesis química , Agonistas del Receptor Purinérgico P1 , Adenosina/análogos & derivados , Adenosina/química , Adenosina/metabolismo , Adenosina/farmacología , Animales , Unión Competitiva , Línea Celular , Corteza Cerebral/metabolismo , Cricetinae , AMP Cíclico/biosíntesis , Humanos , Técnicas In Vitro , Ensayo de Unión Radioligante , Ratas , Receptor de Adenosina A3 , Receptores Purinérgicos P1/metabolismo , Relación Estructura-ActividadRESUMEN
The influence of nitro substituents on the properties of adenosine and 1-deazaadenosine was studied. Combination of a nitro group at the 2-position with several N6 substituents such as cyclopentyl and m-iodobenzyl gave a series of analogues with good adenosine receptor affinity, showing directable selectivity for the A1, A2A and A3 adenosine receptor subtypes.
Asunto(s)
Adenosina/análogos & derivados , Adenosina/metabolismo , Tubercidina/análogos & derivados , Adenosina/síntesis química , Animales , Sitios de Unión , Humanos , Ligandos , Unión Proteica , Agonistas del Receptor Purinérgico P1 , Ensayo de Unión Radioligante , Ratas , Receptor de Adenosina A2A , Receptor de Adenosina A3 , Receptores Purinérgicos P1/metabolismo , Tubercidina/síntesis química , Tubercidina/metabolismoRESUMEN
An extract of a suspension culture of Tabernaemontana pandacaqui Poir. was fractionated by centrifugal partition chromatography. Aliquots were tested in an adenosine A1 receptor binding assay. This led to the isolation and identification of linoleic acid, which proved to be a noncompetitive inhibitor. This "false positive"effect also extended to some other binding assays.
Asunto(s)
Ácido Linoleico/aislamiento & purificación , Ácido Linoleico/metabolismo , Extractos Vegetales/química , Receptores Purinérgicos P1/metabolismo , Animales , Encéfalo/metabolismo , Células Cultivadas , Cromatografía Liquida , Técnicas In Vitro , Indicadores y Reactivos , Ácido Linoleico/farmacología , Extractos Vegetales/farmacología , Antagonistas de Receptores Purinérgicos P1 , Ensayo de Unión Radioligante , Ratas , Receptores Opioides/metabolismoRESUMEN
Novel as well as known 5'-N-substituted carboxamidoadenosines were prepared via new routes that provided shorter reaction times and good yields. Binding affinities were determined for rat A1 and A2A receptors and human A3 receptors. EC50 values were determined for cyclic AMP production in CHO cells expressing human A2B receptors. On all receptor subtypes relatively small substituents on the carboxamido moiety were optimal. Selectivity for the A3 receptor was found for several analogues (1a, 1d, 1h, and 1k). On A1 receptors a number of compounds, but not 5'-N-ethylcarboxamidoadenosine (NECA, 1b), showed small GTP shifts, which could be indicative of lower intrinsic activities at the A1 receptor. At the A2B receptor, derivatives 1i-k with modified ethyl substituents had reduced activities compared to the A2B reference agonist NECA (1b). Thiocarboxamido derivatives (8b and 8c) displayed considerable although decreased A2B receptor activity. The X-ray structure determination of compound 8b was carried out. Due to intramolecular hydrogen bonding between the carboxamido NH and the purine N3 in the crystal structure, the ribose moiety of this compound is in a syn conformation. However, theoretical calculations support that NECA (1b), and less so 8b, can readily adopt both the syn and the anti conformation, therefore not excluding the proposed anti mode of binding to the receptor.
Asunto(s)
Adenosina/análogos & derivados , Adenosina/síntesis química , Agonistas del Receptor Purinérgico P1 , Adenosina/química , Adenosina/farmacología , Animales , Células CHO , Línea Celular , Corteza Cerebral/metabolismo , Cuerpo Estriado/metabolismo , Cricetinae , Cristalografía por Rayos X , AMP Cíclico/biosíntesis , Humanos , Técnicas In Vitro , Conformación Molecular , Ensayo de Unión Radioligante , Ratas , Receptores Purinérgicos P1/metabolismo , Relación Estructura-ActividadRESUMEN
5'-(Alkylthio)-substituted analogues of N6-benzyl- and N6-(3-iodobenzyl)adenosine were synthesized in 37-61% overall yields. The affinities of these compounds for the adenosine A1, A2A, and A3 receptors were determined using rat brain cortex, rat brain striata, and stably transfected human A3 receptors in HEK 293 cells, respectively. The compounds proved to be selective for the adenosine A3 receptor and displayed affinities in the nanomolar range. Compounds 8, 10, and 11 had the highest affinities for the A3 receptor with Ki values ranging from 8.8 to 27.7 nM. In the N6-benzyl series, compound 4 (LUF 5403), with a 5'-methylthio group, maintained a reasonable affinity and had the highest selectivity for the A3 receptor. Compound 12 (LUF 5411), with an N6-(3-iodobenzyl) group and a 5'-(n-propylthio) substituent, had the highest A3 selectivity of all of the compounds and also displayed high affinity for this receptor (Ki = 44.3 nM). The compounds were also evaluated for their ability to stimulate [35S]GTPgamma[S] binding in cell membranes expressing the human adenosine A3 receptor. It appeared that the N6,5'-disubstituted adenosine derivatives behaved as partial agonists. Compounds 2, 4, 8, and 10 had the highest intrinsic activities. Additionally, when tested in a cAMP assay, these compounds also behaved as partial agonists.
Asunto(s)
Adenosina/análogos & derivados , Adenosina/síntesis química , Agonistas del Receptor Purinérgico P1 , Adenosina/química , Adenosina/farmacología , Animales , Células CHO , Línea Celular , Corteza Cerebral/metabolismo , Cuerpo Estriado/metabolismo , Cricetinae , AMP Cíclico/biosíntesis , Guanosina 5'-O-(3-Tiotrifosfato)/metabolismo , Humanos , Técnicas In Vitro , Ensayo de Unión Radioligante , Ratas , Receptor de Adenosina A3 , Receptores Purinérgicos P1/metabolismoRESUMEN
Various adenosine analogues were tested at the adenosine A2B receptor. Agonist potencies were determined by measuring the cyclic AMP production in Chinese Hamster Ovary cells expressing human A2B receptors. 5'-N-Substituted carboxamidoadenosines were most potent. 5'-N-Ethylcarboxamidoadenosine (NECA) was most active with an EC50 value of 3.1 microM. Other ribose modified derivatives displayed low to negligible activity. Potency was reduced by substitution on the exocyclic amino function (N6) of the purine ring system. The most active N6-substituted derivative N6-methyl-NECA was 5 fold less potent than NECA. C8- and most C2-substituted analogues were virtually inactive. 1-Deaza-analogues had a reduced potency, 3- and 7-deazaanalogues were not active.
Asunto(s)
Adenosina-5'-(N-etilcarboxamida)/análogos & derivados , Adenosina/análogos & derivados , Agonistas del Receptor Purinérgico P1 , Adenosina/farmacología , Adenosina-5'-(N-etilcarboxamida)/farmacología , Animales , Células CHO , Cricetinae , AMP Cíclico/biosíntesis , Humanos , Receptor de Adenosina A2B , Proteínas Recombinantes/agonistasRESUMEN
The adenosine antagonist 9-chloro-2-(2-furanyl)[1,2,4]triazolo[1, 5-c]quinazolin-5-amine (CGS 15943) binds nonselectively to human A1, A2A, and A3 receptors with high affinity. Acylated derivatives and one alkyl derivative of the 5-amino group and other modifications were prepared in an effort to enhance A2B or A3 subtype potency. In general, distal modifications of the N5-substituent were highly modulatory to potency and selectivity at adenosine receptors, as determined in radioligand binding assays at rat brain A1 and A2A receptors and at recombinant human A3 receptors. In Chinese hamster ovary cells stably transfected with human A2B receptor cDNA, inhibition of agonist-induced cyclic AMP production was measured. An N5-(2-iodophenyl)acetyl derivative was highly selective for A2A receptors. An (R)-N5-alpha-methyl(phenylacetyl) derivative was the most potent derivative at A3 receptors, with a Ki value of 0.36 nM. A bulky N5-diphenylacetyl derivative, 13, displayed a Ki value of 0. 59 nM at human A3 receptors and was moderately selective for that subtype. Thus, a large, nondiscriminating hydrophobic region occurs in the A3 receptor in proximity to the N5-substituent. A series of straight-chain N5-aminoalkylacyl derivatives demonstrated that for A2B receptors the optimal chain length occurs with three methylene groups, i.e., the N5-gamma-aminobutyryl derivative 27 which had a pA2 value of 8.0 but was not selective for A2B receptors. At A1, A2A, and A3 receptors however the optimum occurs with four methylene groups. An N5-pivaloyl derivative, which was less potent than 27 at A1, A2A, and A3 receptors, retained moderate potency at A2B receptors. A molecular model of the 27-A2B receptor complex based on the structure of rhodopsin utilizing a "cross-docking" procedure was developed in order to visualize the environment of the ligand binding site.
Asunto(s)
Antagonistas de Receptores Purinérgicos P1 , Quinazolinas , Quinazolinas/farmacología , Triazoles , Triazoles/farmacología , Animales , Células CHO , Corteza Cerebral/metabolismo , Cricetinae , AMP Cíclico/antagonistas & inhibidores , Humanos , Modelos Moleculares , Conformación Molecular , Conformación Proteica , Quinazolinas/síntesis química , Quinazolinas/química , Quinazolinas/metabolismo , Ratas , Receptor de Adenosina A2A , Receptor de Adenosina A2B , Receptor de Adenosina A3 , Receptores Purinérgicos P1/biosíntesis , Receptores Purinérgicos P1/química , Proteínas Recombinantes/antagonistas & inhibidores , Proteínas Recombinantes/biosíntesis , Relación Estructura-Actividad , Triazoles/síntesis química , Triazoles/química , Triazoles/metabolismoRESUMEN
5'-(Alkylthio)-, 5'-(methylseleno)-, and 5'-(alkylamino)-substituted analogues of N6-cyclopen-tyladenosine (CPA) were synthesized in 30-50% overall yields. The affinities of these compounds for the adenosine A1 and A2A receptors were determined in rat brain membranes. The 5'-substituted CPA analogues proved selective for the adenosine A1 receptors, displaying affinities in the nanomolar range. The compounds were also evaluated for their ability to stimulate [35S]GTP gamma S binding, also in rat brain membranes. The Ki values in receptor binding studies corresponded well to the EC50 values thus obtained. Intrinsic activities of the compounds were tested in vitro by determining the GTP shift in receptor binding studies as well as the maximal binding of [35S]GTP gamma S. It appeared that the 5'-thio and 5'-seleno derivatives in particular behaved as partial agonists.
Asunto(s)
Adenosina/análogos & derivados , Adenosina/síntesis química , Receptores Purinérgicos P1/metabolismo , Adenosina/química , Adenosina/farmacocinética , Adenosina/farmacología , Animales , Encéfalo/metabolismo , Membrana Celular/metabolismo , Guanosina 5'-O-(3-Tiotrifosfato)/metabolismo , Cinética , Agonistas del Receptor Purinérgico P1 , Ratas , Receptor de Adenosina A2A , Relación Estructura-ActividadRESUMEN
The present study explores the C-3' site of the 3-deoxy-3-xylofuranosyl ring of nucleoside analogues with an adenine or N6-cyclopentyladenine (CPA) base moiety and evaluates the effect on adenosine receptor affinity. Two series of sugar-modified adenosines, i.e., 3'-amido-3'-deoxyadenosines and 3'-amidated 3'-deoxyxylofuranosyladenines, were synthesized and tested for their affinity at A1 and A2a receptors in rat brain cortex and rat striatum, respectively. The modest affinity found in the "xylo series" prompted us to synthesize the corresponding N6-cyclopentyl derivatives, which proved to be well accommodated by the A1 receptors with potencies in the lower nanomolar range. This represents a new perspective in the purinergic field. The absence of a GTP-induced shift, i.e., the ratio between the affinities measured in the presence and absence of 1 mM GTP indicates an antagonistic behavior of this new class of CPA analogues.
Asunto(s)
Adenosina/análogos & derivados , Antagonistas de Receptores Purinérgicos P1 , Adenosina/síntesis química , Adenosina/farmacología , Animales , Sitios de Unión , Cristalografía por Rayos X , Ensayo de Unión Radioligante , Ratas , Receptores Purinérgicos P1/metabolismo , Xantinas/farmacologíaRESUMEN
In this study we investigated the relationship between the pharmacokinetics and the cardiovascular and electroencephalogram (EEG) effects of three adenosine agonists with differing lipophilicity. Conscious normotensive rats received either 600 microg/kg N6-(p-sulphophenyl) adenosine (SPA), 200 microg/kg N6-cyclopentyladenosine (CPA) or 600 microg/kg 1-deaza-2-chloro-N6-cyclopentyladenosine (DCCA) in a 5-min intravenous infusion. Changes in haemodynamics and EEG were monitored in conjunction with arterial blood sampling to determine blood concentrations of the compounds. The three adenosine agonists showed large differences in pharmacokinetic properties, resulting in terminal half-lives of 66 +/- 10, 8.2 +/- 0.4 and 24 +/- 1 min (mean +/- SEM) for SPA, CPA, and DCCA respectively. SPA had a significantly lower blood clearance relative to CPA and DCCA, whereas DCCA had the largest volume of distribution and degree of plasma protein binding. The relationship between concentration and heart rate could be described adequately by the sigmoidal Emax model. For SPA, CPA, and DCCA the EC50 values based on free drug concentrations were 423 +/- 92, 1.8 +/- 0.4 and 9.5 +/- 1.1 nM respectively. These in vivo values correlated closely with the affinity of the compounds for the adenosine A1 receptor as determined in radioligand binding studies, with corresponding Ki values of 1410 +/- 220, 4.7 +/- 0.6 and 102 +/- 74 nM (mean +/- SEM) respectively. In the EEG, only CPA produced a small decrease in the amplitude of beta waves. This study demonstrates that the three adenosine analogues have large differences in pharmacokinetics, which complicates comparison of their cardiovascular and central responses simply on the basis of dose. The application of an integrated PK/PD approach permits estimates of potency and activity which are independent of underlying dose and pharmacokinetics.
Asunto(s)
Adenosina/análogos & derivados , Electroencefalografía/efectos de los fármacos , Agonistas del Receptor Purinérgico P1 , Adenosina/química , Adenosina/farmacocinética , Adenosina/farmacología , Animales , Disponibilidad Biológica , Presión Sanguínea/efectos de los fármacos , Semivida , Frecuencia Cardíaca/efectos de los fármacos , Masculino , Tasa de Depuración Metabólica , Ratas , Ratas WistarRESUMEN
A glutamic acid residue in the first transmembrane domain of the human adenosine A2A receptor was mutated to glutamine. Radioligand binding studies on COS-7 cell membranes expressing either the wild-type or the mutant receptor revealed that the affinity of the prototypic agonist CGS21680 (2-[4-[(2-carboxyethyl)phenyl]ethylamino]-5'-N-ethylcarboxamidoadenosine ) for the mutant receptor was 15-fold lower than for the wild-type receptor. This was confirmed in functional studies with intact cells. The EC50 values of CGS21680 for the stimulation of cAMP production differed in a similar way. Antagonists of various chemical structure were equally effective on both mutant and wild-type receptors, thus the mutation selectively diminishes agonist affinity. We propose an indirect perturbation of the binding site, perhaps through a proton transfer mechanism as suggested by molecular modelling.
Asunto(s)
Ácido Glutámico/metabolismo , Receptores Purinérgicos P1/genética , AMP Cíclico/biosíntesis , Humanos , Mutagénesis Sitio-Dirigida , Agonistas del Receptor Purinérgico P1 , Ensayo de Unión Radioligante , Receptores Purinérgicos P1/metabolismoRESUMEN
The synthesis and biological evaluation of N6, C8-disubstituted derivatives of adenosine as potential partial agonists for adenosine receptors is described. Via three routes, two series of compounds were prepared, viz., N6-cyclopentyladenosine derivatives 3a-e and C8-(cyclopentylamino)adenosine analogs 3e and 9a-d, respectively. The X-ray structure determination of one of these compounds, N6-ethyl-8(cyclopentylamino)adenosine (9b), was carried out (orthorhombic, space group P2(1)2(1)2(1) (No. 19) with a = 11.039(3), b = 8.708(2), and c = 24.815(12) angstrom, Z=4,R1=0.0974,R2(W) = 0.2455). Due to intramolecular hydrogen bonding, the ribose moiety of this compound is in an anti conformation. The compounds were tested in vitro in radioligand binding studies, yielding their affinities for A1 and A2a adenosine receptors. All compounds appeared A1 selective, with affinities in the high nanomolar, low micromolar range. On A1 receptors the so-called GTP shift was also determined, i.e., the ratio between the affinities measured in the presence and absence of 1 mM GTP. All GTP shifts (values between 1.1 and 3.8) were lower than the GTP shift for CPA (6.0). This GTP shift appeared indicative for partial agonism in vivo, since the N6-cyclopentyladenosine derivatives showed lower intrinsic activities than the prototypic full agonist N6-cyclopentyladenosine on the decrease in heart rate in conscious, normotensive rats.
Asunto(s)
Adenosina/análogos & derivados , Agonistas del Receptor Purinérgico P1 , Adenosina/síntesis química , Adenosina/química , Adenosina/metabolismo , Adenosina/farmacología , Animales , Antihipertensivos/farmacología , Unión Competitiva , Presión Sanguínea/efectos de los fármacos , Encéfalo/metabolismo , Cristalografía por Rayos X , Guanosina Trifosfato/farmacología , Frecuencia Cardíaca/efectos de los fármacos , Espectroscopía de Resonancia Magnética , Modelos Moleculares , Estructura Molecular , Fenetilaminas/metabolismo , Unión Proteica , Ratas , Ratas Wistar , Receptores Purinérgicos P1/metabolismo , Xantinas/metabolismoRESUMEN
We have adopted a practical three-step route for the synthesis of 2'- and 3'-deoxy analogues of N6-substituted adenosines: protection of the hydroxyl groups, replacement of the N6-amino by a better leaving group, and combined deprotection and N6-amination in the last step. This route was used to synthesize deoxy analogues of CPA, CHA, and R- and S-PIA. The compounds were tested on the adenosine A1 and A2a receptors in our search for partial agonists for these receptors. The GTP shift was used as an in vitro measure for the intrinsic activity of these compounds; the in vivo intrinsic activities of the deoxy analogues of CPA and R-PIA were determined in the rat cardiovascular system. Thus, it was shown that the hydroxyl groups are determinants for the affinity and intrinsic activity of these analogues. Removal of the 2'- and 3'-hydroxyl groups affects affinity and intrinsic activity, whereas removal of the 5'-hydroxyl group decreases only affinity.
Asunto(s)
Adenosina/análogos & derivados , Agonistas del Receptor Purinérgico P1 , Adenosina/farmacología , Animales , Presión Sanguínea/efectos de los fármacos , Guanosina Trifosfato/farmacología , Frecuencia Cardíaca/efectos de los fármacos , Masculino , Ratas , Ratas Wistar , Ribosa , Relación Estructura-ActividadRESUMEN
A series of 8-substituted adenosine and theophylline-7-riboside analogues (28 and 9 compounds, respectively) was tested on adenosine A1 and A2A receptors as an extensive exploration of the adenosine C8-region. Alkylamino substituents at the 8-position cause an affinity decrease for adenosine analogues, but an affinity increase for theophylline-7-riboside derivatives. The affinity decrease is probably due to a direct steric hindrance between the C8-substituent and the binding site as well as to electronic effects, not to a steric influence on the ribose moiety to adopt the anti conformation. The 8-substituents increase the affinity of theophylline-7-riboside analogues probably by binding to a lipophilic binding site. The intrinsic activity was tested in vitro for some 8-substituted adenosine analogues, by determining the GTP shift in receptor binding studies and the inhibition of adenylate cyclase in a culture of rat thyroid FRTL-5 cells, and in vivo in the rat cardiovascular system for 8-butylaminoadenosine. Thus, it was shown that 8-ethyl-, 8-butyl-, and 8-pentylamino substituted analogues of adenosine may be partial agonists in vitro, and that 8-butylaminoadenosine is a partial agonist for the rat cardiovascular A1 receptor in vivo.
Asunto(s)
Adenosina/análogos & derivados , Adenosina/farmacología , Agonistas del Receptor Purinérgico P1 , Teofilina/análogos & derivados , Teofilina/farmacología , Adenosina/química , Adenilil Ciclasas/metabolismo , Animales , Células Cultivadas , Frecuencia Cardíaca/efectos de los fármacos , Técnicas In Vitro , Cinética , Ratas , Teofilina/química , Xantinas/farmacologíaRESUMEN
Theophylline-7-riboside was evaluated as a partial agonist for rat adenosine receptors. Radioligand binding experiments were performed on both A1 and A2a adenosine receptors, using several methodologies to discriminate between agonists and antagonists. Mainly from thermodynamic data it was concluded that on A1 receptors theophylline-7-riboside had characteristics intermediate between full agonists, such as N6-cyclopentyladenosine, and full antagonists, such as the xanthines. The partial agonistic behaviour of theophylline-7-riboside was further explored in second messenger studies in intact cells. In FRTL-5 rat thyroid cells theophylline-7-riboside behaved as a partial agonist for A1 receptors, slightly inhibiting forskolin-stimulated cyclic AMP levels. The implications of these biochemical findings were further analysed in in vivo pharmacology. The infusion of theophylline-7-riboside in conscious, normotensive rats led to marked changes in cardiovascular parameters, although less outspoken than observed with full agonists for either A1 or A2a receptors. The concomitant determination of the blood concentrations of theophylline-7-riboside and its metabolite theophylline allowed the estimation of in vivo pharmacokinetic and pharmacodynamic parameters. Thus, the EC50 value of theophylline-7-riboside for lowering the mean arterial pressure was 47 +/- 12 micrograms/ml blood. The short duration of action of theophylline-7-riboside makes it improbable that its metabolite theophylline interferes with its effects. In conclusion, theophylline-7-riboside is one of the first partial agonists for adenosine receptors. It may serve as a tool in further investigations of adenosine receptor partial agonism.
Asunto(s)
Agonistas del Receptor Purinérgico P1 , Teofilina/agonistas , Xantinas/farmacología , Animales , Células Cultivadas , Colforsina/farmacología , Guanosina Trifosfato , Ratas , Receptores Purinérgicos P1/efectos de los fármacos , Temperatura , Teofilina/farmacología , Xantina , Xantinas/químicaRESUMEN
The neuropeptide substance P (SP) has been shown to play an important role as a mediator of neurogenic inflammation. Moreover, in vitro SP is capable of modulating the activity of lymphocytes, monocytes and polymorphonuclear cells. We have examined one of the early events that occur after addition of SP to human peripheral blood mononuclear cells (PBMC). Addition of 10(-6)-10(-4) M SP to human peripheral blood mononuclear cells results in a dose-dependent rise in intracellular calcium concentration as determined by FACS analysis. We show that the effect of SP cannot be attenuated by the SP receptor antagonist [D-Pro4,D-Trp7,9]-SP(4-11), indicating that the response is not mediated via a SP receptor. Amphiphilic peptides like SP appear to have the capacity to insert themselves into the cell membrane and interact directly with intracellular proteins. This hypothesis is supported by the fact that the amphiphilic analogue of SP, [D-Pro2,D-Phe7,D-Trp9]-SP, is capable of inducing a calcium response in our system, although it is known as an SP receptor antagonist. Functionally, we show that SP increases the proliferative response of T cells induced by suboptimal concentrations of the mitogen PHA. These data provide evidence of a potential role of SP in the regulation of lymphocyte activation.